MDS Pharma Services Strengthens Therapeutic Focus on Respiratory and…
The News Review:
- MDS Pharma Services Strengthens Therapeutic Focus on Respiratory and…
- Clinquest Group appoints Dr. Louis Van de Ven MD Ph.D. as CE/CM…
- World Hepatitis Alliance Calls n Governments To Take Urgent Action…
- New Latent TB Drug Saves Lives Money
- New Prognostic Markers For Gastric Cancer Patients
MDS Pharma Services Strengthens Therapeutic Focus on Respiratory and…
Earthtimes – May 20, 2008
adult population is currentlyobese and more than 200 million people worldwide have diabetes. The WorldHealth rganization estimates that 300 million people suffer from asthma themost common chronic disease among children and that 210 million people haveCPD which is predicted to become the fourth leading cause of death worldwideby 2030. "Pharmaceutical companies are pursuing clinical research programs toaddress these disorders and we have made a strategic decision to become aleader in these key therapeutic arenas by establishing dedicated teams headedby experienced medical professionals" said MDS Pharma Services PresidentDavid Spaight. "In the past 10 years MDS Pharma Services has managed over 150clinical projects involving respiratory conditions and metabolic disorders. With expert project teams in Africa Asia Pacific Europe Latin America andNorth America we can offer our clients worldwide access to patients withthese conditions. Tisserand has held a number of senior positions in clinical operationsand project management at MDS Pharma Services.
Clinquest Group appoints Dr. Louis Van de Ven MD Ph.D. as CE/CM…
Genetic Engineering News – Genetic Engineering News (press release) – May 20, 2008
Louis Van de Ven MD Ph. asChief Executive and Chief Medical fficer of its subsidiary ClinquestEurope BV (ss The Netherlands). Louis Van de Ven joins Clinquest Europe from Merck Netherlandswhere he held the position of Medical Director responsible forclinical research and medical affairs for Europe.
World Hepatitis Alliance Calls n Governments To Take Urgent Action…
Medical News Today – Medical News Today (press release) – May 20, 2008
“The challenge for viral hepatitis is to make healthcare authorities and policy makers aware that this disease if not tackled today will be a major burden in the next 20 years as today’s patients will develop liver cancer. It is better to act today than be unable to react tomorrow” said Professor Driss Jamil a specialist in hepatitis B and C at the Department of Medicine University of Casablanca Morocco and one of 12 members of the World Hepatitis Alliance Public Health Panel. Professor Greg Dore Head of the Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and Clinical Research University of New South Wales Sydney Australia and also a member of the Public Health Panel added “Increased awareness and understanding of the public health impact of chronic viral hepatitis is required to mobilise action on proven prevention and care strategies. Awareness raising will promote advocacy improve global funding and reduce the stigma and discrimination that affect many people with chronic viral hepatitis. 5 million people a year – ne in every three people on the planet has been exposed to either or both viruses – Most of the 500 million infected do not know World Hepatitis Day World Hepatitis Day is being observed on Monday 19 May and marks a brand new entirely patient-led initiative.
New Latent TB Drug Saves Lives Money
Washington Post – May 20, 2008
correction {margin-top:8px;padding-top:10px;margin-bottom:8px;border-bottom:1px solid #CCCCCC;padding-bottom:10px;font-family:arialsans-serif;font-size:11px;color:#333333;}. correction strong {color:#CC0000;text-transform:uppercase;}New Latent TB Drug Saves Lives MoneyTuesday May 20 2008; 12:00 AMTUESDAY May 20 (HealthDay News) — Using the drug Rifampin to treat people with latent tuberculosis saves time money and lives new research shows. “We found that using a therapy of four months of Rifampin instead of the current nine months of Isoniazid costs significantly less for the health-care system” lead analyst Anne Aspler of the respiratory epidemiology and clinical research unit at McGill University’s Montreal Chest Clinic said in a prepared statement. “verall Rifampin costs about $484 less per patient treated which if we assume that four months of Rifampin has a least equal efficacy to nine months of Isoniazid represents an added savings to the health system of more than $10000 per patient prevented from developing [full-blown] TB disease. And because of improvements in compliance we are actually preventing more cases. This treatment can save money as well as lives” Aspler said. The study was expected to be presented Tuesday at the American Thoracic Society’s International Conference in Toronto.
New Prognostic Markers For Gastric Cancer Patients
Science Daily – Science Daily (press release) – May 20, 2008
The team identified that syndecan-1 E-cadherin and integrins highly correlated with each other as intracellular adhesion molecular complexes. We suggest the results of co-examination of them can be important indexes for the prognosis of gastric carcinoma. In the view of the authors to date no clear mechanism has been found to explain the interaction of the three molecules and no clinical research has been done to verify the findings. Traditional clinicopathologic factors and several interesting molecules including cell cycle regulation factors such as p27 or cyclin E cell adhesion molecules such as E-cadherin angiogenic factors such as vascular endothelial growth factor and placenta growth factor oncogenes such as c-erbB2 and c-myc and tumor suppressor genes such as p53 have been reported to correlate to the prognosis of gastric cancer patients. Cell adhesion is one of important steps in the multi-step process of gastric cancer pathogenesis. Further research should collect more samples and emphasize the importance of studying multiple genetic alterations in concert. Journal reference:Chu YQ Ye ZY Tao HQ Wang YY Zhao ZS.
Written by admin on May 20th, 2008 with
no comments.
Read more articles on News.